Brimonidine P · DIN 02301334 · 0.15% · Oph Sol
Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Brimonidine P · DIN 02301334
Manufacturer: A A Pharma Inc.; listing date 2008-10-01
Health Canada: Marketed since 2021-10-20 · brand BRIMONIDINE P · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.15 %/W/V · company Aa pharma inc · schedule Prescription
Brimonidine P: Formulary list price $2.03 per unit (the source does not state the unit; exact figure $2.0305). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02301334)
Source record
DIN 02301334: Brimonidine P
Raw flags: sec12=Y, sec3=Y
Item: 523600107; group id 614; item number 1580; lccId 00082; manufacturer id AAP
Source form: Oph Sol; strength: 0.15%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.0305; ministry $2.0305
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02301334
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78666
Interchangeable products
Alphagan P · DIN 02248151 · $2.0305
Shortage status: not checked (no credentials)